Blood 2011, 117:1834-1839. R1 Seon-Hye Kim Arnaud Jaccarda and Olivier Hermine Journal conference.

Slides:



Advertisements
Similar presentations
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
Advertisements

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Facon T et al. Proc ASH 2013;Abstract 2.
1Coiffier B et al. Proc ASH 2010;Abstract 114.
How I treat relapsed and refractory Hodgkin lymphoma blood Prepublished online January 24, 2011; dr.kaji 1392.
Supervisor: Vs 楊慕華醫師 Presenter: CR 周益聖醫師 N Engl J Med 2012;367:
Palumbo A et al. Proc ASH 2012;Abstract 446.
LaCasce A et al. Proc ASH 2014;Abstract 293.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma: Ginna G. Laport, MD Associate Professor of Medicine Division of Blood &
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.
Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Palumbo A et al. Proc ASH 2014;Abstract 175.
Rituximab efficacy in other haematological malignancies Christian Buske.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.
Should whole brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG-1 randomized.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.
Cell Suicide in Health and Disease
The Bruton’s Tyrosine Kinase Inhibitor PCI is Highly Active as Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary.
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.
12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.
Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.
Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.
EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.
Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib,
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Blood : R2 임규성.  Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by low platelet counts and may be responsible.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
J Clin Oncol August Vol 28 R2. 석화영 / Pf. 윤휘중.
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
Ashkan Emadi 1, Steven D. Gore Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, United States Blood Reviews 24 (2010)
Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,
Geisler C et al. Proc ASH 2011;Abstract 290.
Evaluation of CD19 specific Chimeric Antigen Receptor T cells (CAR19 T-cells) as an optimal bridge to allogeneic transplantation. Phase I trial for patients.
R1.이용석 / modulator pf.한재준.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Shustov AR et al. Proc ASH 2010;Abstract 961.
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
Oki Y et al. Proc ASH 2013;Abstract 252.
Mateos MV et al. Proc ASH 2013;Abstract 403.
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Goede V et al. Proc ASH 2014;Abstract 3327.
Fowler NH et al. Proc ASH 2011;Abstract 99.
Presented by: Dr.Naser Shagerdi Esmaeli
Presentation transcript:

Blood 2011, 117: R1 Seon-Hye Kim Arnaud Jaccarda and Olivier Hermine Journal conference

 Extranodal NK/T-cell lymphoma, nasal type, a rare and highly aggressive disease with a grim prognosis. more frequent in Asia & Central/South America than in Europe & North America. thought to arise from NK cells or, γδ or αβ cytotoxic T cells and show a tight association with EBV. usually diagnosed in adults, with a median age in the fifth decade.

 Chemotherapy protocols used for lymphomas are poorly effective, b/o frequent MDR gene expression by tumor cells.  very poor outcome & no standard management for relapsed or refractory disease.  We and others, in small retrospective studies, have observed very good response and survival rates in patients treated with L-asparaginase, a drug with an original antitumoral mechanism not affected by MDR.  NK cells lack asparagine synthase activity, and asparaginase has been shown to induce apoptosis of tumoral NK cells in vitro.  These findings provided the rationale for this open-label phase 2 study of an L-asparaginase containing regimen for patients with relapsed and/or refractory extranodal NK/T-cell lymphoma.

 Combine L-asparaginase with MTX, a drug insensitive to the multidrug resistance pathway, because of its well-known synergistic effect with asparaginase and its ability to prevent CNS involvement.  Dexamethasone was added because T-cell lymphomas are usually sensitive to corticosteroids and dexamethasone seems to be associated with a lower risk of thrombosis when given with L-asparaginase.

Exclusion criteria Previous asparaginase administration Pregnancy or breast feeding Contraindication to one of the trial drugs ( uncontrolled DM, progressive phlebitis, renal or hepatic impairment contraindicating MTX or L-asparaginase) Another unrelated severe progressive disease or malignancy Eligibility criteria < 18 yrs old Relapsed or refractory extra-nodal NK/T cell lymphoma biopsy-proven diagnosis of NK-T cell lymphoma, nasal type CD3 ε+, CD20- phenotype, cytotoxic profile, evidence of EBV infection

D1 D2 D3 D4 D5 D6 D7 D8 D21(1 cycle ) 3 cycle MTX 3g/m² day 1 Oral dexamethasone 40mg day1~4 L-asparaginase 6000 units/m² IM day 2,4,6,8 * Antithrombin & fibrinogen serum levels 1.before each injection of asparaginase hours after the last one of each cycle. 3. antithrombin levels <60% of normal or fibrinogen levels <0.5 g/L  received replacement therapy. * Alkaline hydration and leucoverin rescue with MTX * Bactrm and valaciclovir prophylaxis 1.Localized disease  RTx 2. Disseminated disease  BEAM regimen + pph stem cell infusion

 Primary end point ◦ the complete response rate after 3 cycles of AspaMetDex  Secondary end points ◦ overall response and progression rate ◦ overall survival (OS), progression-free survival (PFS) ◦ tolerability ◦ toxicity.  Responses assessment ◦ 3 weeks after the 3 cycle of the AspaMetDex protocol ◦ 1 month after the end of treatment.

 March 2006 ~ October 2008  13 centers prospectively enrolled a total of 20 patients.  One patient was excluded after pathologic review.

 In the International Peripheral T-cell Lymphoma Project, ◦ the median survival time : NK/T-cell lymphoma was only 7.8 months ◦ the worst survival time among all the peripheral T-cell lymphoma categories.  Almost 80%(14/18) of the pts responded to asparaginase containing regimen, and 11 pts entered CR(61%) after 3 cycles.  CR rate ① twice AspaMetDex > 1 st line CHOP or salvage regimen (etoposide, ifosfamide, MTX, and PD) ② 50% AspaMetDex at stage IV, 15% conventional CTx at stage III or IV

 The responses occurred very rapidly, usually after the 1 st cycle as shown in responding patients by the rapid drop in EBV serum DNA, which was, as already published ; good marker of outcome.  Why NK/T tumor cells are so sensitive to asparagine privation? ◦ not completely understood ◦ usual absence of asparagine synthetase gene expression probably plays a role.

 The precise contribution of MTX and dexamethasone to the efficacy of the AspaMetDex protocol : not known  Anti-asparaginase Ab : Worse survival & more frequent relapse or progression (6 /8 pts with antibodies vs 2/8 pts without antibodies).  Strategies may be used to overcome this problem ① early antibody detection ② routine switch btw asparaginase molecules after 2 cycles ③ the use of pegylated asparaginase(less immunogenic)  because no other effective salvage regimen is available and very short survival of non-responding and relapsing patients in our trial

 One striking result of our study is the difference in outcome between relapsing and refractory patients as 7 of 11 of the former are in persistent remission, whereas only one of 8 of the latter is still alive.  Higher frequency of disseminated disease in the refractory group (5 of 8 stage IV patients) than in the relapsing group (2 of 11 stage IV patients).  Another possibility might be that tumor cells from refractory patients have developed specific mechanisms of resistance to CTx, including asparaginase.

 In conclusion, the results of this phase 2 trial confirm the efficacy of L- asparaginase in patients with extranodal NK/T-cell lymphoma.  Patients with NK/T-cell lymphoma must not be placed on supportive care without first trying an asparaginase-containing regimen, even if their disease is disseminated, refractory to previous treatments, or in relapse.  This studies may already justify trials of first-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma, combined with irradiation for patients with localized disease and high-dose treatment with stem cell support for patients with disseminated disease.